| Gut microbiota and intestinal FXR mediate the clinical benefits of metformin L Sun, C Xie, G Wang, Y Wu, Q Wu, X Wang, J Liu, Y Deng, J Xia, B Chen, ... Nature medicine 24 (12), 1919-1929, 2018 | 737 | 2018 |
| Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction C Jiang, C Xie, Y Lv, J Li, KW Krausz, J Shi, CN Brocker, D Desai, ... Nature communications 6 (1), 10166, 2015 | 497 | 2015 |
| Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead WH Goodson III, L Lowe, DO Carpenter, M Gilbertson, A Manaf Ali, ... Carcinogenesis 36 (Suppl_1), S254-S296, 2015 | 337 | 2015 |
| Adaptation of the human aryl hydrocarbon receptor to sense microbiota-derived indoles TD Hubbard, IA Murray, WH Bisson, TS Lahoti, K Gowda, SG Amin, ... Scientific reports 5 (1), 12689, 2015 | 324 | 2015 |
| Colorectal cancer liver metastasis: evolving paradigms and future directions LR Zarour, S Anand, KG Billingsley, WH Bisson, A Cercek, MF Clarke, ... Cellular and molecular gastroenterology and hepatology 3 (2), 163-173, 2017 | 275 | 2017 |
| Estrogen-Like Activity of Perfluoroalkyl Acids In Vivo and Interaction with Human and Rainbow Trout Estrogen Receptors In Vitro AD Benninghoff, WH Bisson, DC Koch, DJ Ehresman, SK Kolluri, ... Toxicological sciences 120 (1), 42-58, 2011 | 234 | 2011 |
| Causes of genome instability: the effect of low dose chemical exposures in modern society SAS Langie, G Koppen, D Desaulniers, F Al-Mulla, R Al-Temaimi, ... Carcinogenesis 36 (Suppl_1), S61-S88, 2015 | 225 | 2015 |
| Environmental immune disruptors, inflammation and cancer risk PA Thompson, M Khatami, CJ Baglole, J Sun, SA Harris, EY Moon, ... Carcinogenesis 36 (Suppl_1), S232-S253, 2015 | 207 | 2015 |
| LSD1 activates a lethal prostate cancer gene network independently of its demethylase function A Sehrawat, L Gao, Y Wang, A Bankhead III, SK McWeeney, CJ King, ... Proceedings of the National Academy of Sciences 115 (18), E4179-E4188, 2018 | 197 | 2018 |
| Modeling of the aryl hydrocarbon receptor (AhR) ligand binding domain and its utility in virtual ligand screening to predict new AhR ligands WH Bisson, DC Koch, EF O’Donnell, SM Khalil, NI Kerkvliet, RL Tanguay, ... Journal of medicinal chemistry 52 (18), 5635-5641, 2009 | 165 | 2009 |
| HDAC turnover, CtIP acetylation and dysregulated DNA damage signaling in colon cancer cells treated with sulforaphane and related dietary isothiocyanates P Rajendran, AI Kidane, TW Yu, WM Dashwood, WH Bisson, CV Löhr, ... Epigenetics 8 (6), 612-623, 2013 | 137 | 2013 |
| The anti-inflammatory drug leflunomide is an agonist of the aryl hydrocarbon receptor EF O'Donnell, KS Saili, DC Koch, PR Kopparapu, D Farrer, WH Bisson, ... PloS one 5 (10), e13128, 2010 | 135 | 2010 |
| TCDD, FICZ, and Other High Affinity AhR Ligands Dose-Dependently Determine the Fate of CD4+ T Cell Differentiation AK Ehrlich, JM Pennington, WH Bisson, SK Kolluri, NI Kerkvliet Toxicological sciences 161 (2), 310-320, 2018 | 134 | 2018 |
| The effect of environmental chemicals on the tumor microenvironment SC Casey, M Vaccari, F Al-Mulla, R Al-Temaimi, A Amedei, ... Carcinogenesis 36 (Suppl_1), S160-S183, 2015 | 128 | 2015 |
| Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs WH Bisson, AV Cheltsov, N Bruey-Sedano, B Lin, J Chen, N Goldberger, ... Proceedings of the National Academy of Sciences 104 (29), 11927-11932, 2007 | 128 | 2007 |
| Identification of a high-affinity ligand that exhibits complete aryl hydrocarbon receptor antagonism KJ Smith, IA Murray, R Tanos, J Tellew, AE Boitano, WH Bisson, ... Journal of Pharmacology and Experimental Therapeutics 338 (1), 318-327, 2011 | 119 | 2011 |
| Metabolic reprogramming and dysregulated metabolism: cause, consequence and/or enabler of environmental carcinogenesis? RB Robey, J Weisz, NB Kuemmerle, AC Salzberg, A Berg, DG Brown, ... Carcinogenesis 36 (Suppl_1), S203-S231, 2015 | 118 | 2015 |
| AHR2 mutant reveals functional diversity of aryl hydrocarbon receptors in zebrafish BC Goodale, JK La Du, WH Bisson, DB Janszen, KM Waters, RL Tanguay PloS one 7 (1), e29346, 2012 | 105 | 2012 |
| Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors M Ceccon, L Mologni, W Bisson, L Scapozza, C Gambacorti-Passerini Molecular Cancer Research 11 (2), 122-132, 2013 | 102 | 2013 |
| α-Keto acid metabolites of organoselenium compounds inhibit histone deacetylase activity in human colon cancer cells H Nian, WH Bisson, WM Dashwood, JT Pinto, RH Dashwood Carcinogenesis 30 (8), 1416-1423, 2009 | 101 | 2009 |
